within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX07_Cabozantinib;
model Cabozantinib 
   extends Pharmacolibrary.Drugs.ATC.L.L01EX07;

  annotation(Documentation(
    info ="<html><body><p>Cabozantinib is an oral multi-kinase inhibitor that targets MET, VEGFR, and other tyrosine kinases. It is approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with advanced solid tumors. Parameters from population pharmacokinetic analyses in clinical studies involving both male and female patients.</p><h4>References</h4><ol><li><p>Campbell, MT, et al., &amp; Habra, MA (2024). Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. <i>The Lancet. Oncology</i> 25(5) 649–657. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(24)00095-0&quot;>10.1016/S1470-2045(24)00095-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38608694/&quot;>https://pubmed.ncbi.nlm.nih.gov/38608694</a></p></li><li><p>Nguyen, L, et al., &amp; Lacy, S (2016). Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib. <i>Journal of clinical pharmacology</i> 56(9) 1130–1140. DOI:<a href=&quot;https://doi.org/10.1002/jcph.714&quot;>10.1002/jcph.714</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26865195/&quot;>https://pubmed.ncbi.nlm.nih.gov/26865195</a></p></li><li><p>Castellano, D, et al., &amp; Jonasch, E (2020). Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. <i>Cancer treatment reviews</i> 89 102062–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ctrv.2020.102062&quot;>10.1016/j.ctrv.2020.102062</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32659623/&quot;>https://pubmed.ncbi.nlm.nih.gov/32659623</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Cabozantinib;
